An award-winning journalist, Derrick has written extensively about user fee negotiations, the FDA budget, FDA travel restrictions and drug advertising compliance. He also was part of the Pink Sheet team covering FDA's first biosimilar advisory committee meetings.
When he's not following FDA, Derrick is keeping close tabs on Indiana Hoosiers basketball.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Derrick Gingery
Rachel Sherman says agency is creating patient affairs staff, but will not undergo reorganization to create an official office.
Deputy Office of New Drugs director says IND evaluation and post-market surveillance could be part of restructuring effort along with changes to application review.
US guidances will be shorter and use a series of bullet points to communicate key ideas, replacing the current longer and wordier format.
Amid confusion about multiple priority and expedited pathways for US generic drug applications, industry asks which are a true advantage.
In interview with the Pink Sheet, US FDA Commissioner says the agency needs new ways for in-house talent to more easily rise to supervisory and executive levels.
US FDA Commissioner Scott Gottlieb sat down with the Pink Sheet and Medtech Insight reporters for an exclusive chat about his ongoing regulatory work and plans for the future.